Detalhe da pesquisa
1.
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
N Engl J Med
; 389(24): 2233-2244, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38091530
2.
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
N Engl J Med
; 387(14): 1279-1291, 2022 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36112399
3.
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
N Engl J Med
; 386(21): 2011-2023, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35544369
4.
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
N Engl J Med
; 387(18): 1673-1687, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260859
5.
Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Solid Organ Transplant Recipients.
J Infect Dis
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513368
6.
Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
J Infect Dis
; 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38349280
7.
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
N Engl J Med
; 385(24): 2241-2251, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34379915
8.
Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials.
Clin Infect Dis
; 76(2): 271-280, 2023 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130187
9.
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.
Ann Intern Med
; 175(9): 1258-1265, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35785530
10.
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial.
J Infect Dis
; 226(10): 1731-1742, 2022 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35535503
11.
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
J Infect Dis
; 220(11): 1816-1825, 2019 10 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31418022
12.
Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
BMC Infect Dis
; 15: 409, 2015 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26437712
13.
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Lancet Infect Dis
; 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38518789
14.
Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape.
Hum Vaccin Immunother
; 19(1): 2153532, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36629006
15.
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.
Nat Commun
; 14(1): 5125, 2023 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37612300
16.
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.
Open Forum Infect Dis
; 10(3): ofad069, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895286
17.
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
Nat Med
; 29(9): 2325-2333, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37653342
18.
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lancet Infect Dis
; 23(9): 1007-1019, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37348519
19.
Safety and Immunogenicity of a 100 µg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
medRxiv
; 2022 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35291289
20.
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
Nat Med
; 28(5): 1042-1049, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35241844